Downloads

  1. Accelerating Complex Generic Drug Development Through Advanced Deformulation 10/13/2026

    With FDA no longer identifying Q1/Q2 differences, applicants bear the diagnostic burden. Reverse engineering now directly affects development speed, cost, and approval.

  2. Endotoxin Control In The Process Development Lab 10/13/2026

    Endotoxin control in E. coli fermentation depends on effective removal, purification, and NaOH cleaning strategies, with risks evolving as manufacturing progresses.

  3. Transforming QC Lab Scheduling In Pharmaceutical Manufacturing 10/13/2026

    QC lab scheduling in GMP facilities often runs on static tools disconnected from production. Synchronizing the two in real time changes how batch release, deviations, and capacity are managed.

  4. Chemically Defined Media System For Scalable Exosome Manufacturing 10/13/2026

    A single fed-batch, chemically defined medium carries MSC and fibroblast cultures from seeding through harvest, extending the exosome collection window and avoiding losses at media exchanges and washes.

  5. Transitioning mRNA Production To cGMP Requires Early Process Engagement 10/9/2026

    Early choices in capping strategy, IVT conditions, raw materials, and downstream design shape yield, cost, and quality in mRNA manufacturing, and can determine whether a cGMP campaign succeeds.

  6. Optimizing GMP Manufacturing Of Lipid Nanoparticles For mRNA Encapsulation 10/9/2026

    Moving mRNA lipid nanoparticle encapsulation from pre-clinical work to cGMP production is often underestimated. Early process parameter definition, raw material control, and scalable mixing determine how low-risk that transition becomes.

  7. The Early Advantage For mRNA 10/9/2026

    Developing mRNA treatments requires expertise in process development and LNP encapsulation for small biotech companies.

  8. Simplify The Encapsulation Process Of Nucleic Acid Payloads With FDmiX Technology 10/9/2026

    Enable a reliable, swift scale-up to cGMP manufacturing for mRNA encapsulation with the high-end FDmiX technology. Discover how to master challenges, streamline production, and enable faster, more predictable development of nucleic acid delivery systems.

  9. Optimizing GMP Manufacturing Of Lipid Nanoparticles 10/9/2026

    Next-generation nucleic acid encapsulation centers on mixing technology, with data on manufacturability, stability, and homogeneity of lipid nanoparticles in a GMP manufacturing context.

  10. New 2X 4,000L Microbial Fermentation Capacity For Your Program Lifecycle 10/9/2026

    Two 4,000L fermenters, run singly or in parallel, extend microbial capacity at mid scale, aiming to carry a program from clinical supply through launch and commercial without changing sites.